Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States.
Krystal Biotech stock last closed at $336.80, down 0.67% from the previous day, and has increased 121.72% in one year. It has overperformed other stocks in the Biotechnology industry by 1.38 percentage points. Krystal Biotech stock is currently +158.08% from its 52-week low of $130.50, and -11.96% from its 52-week high of $382.54.
As of Jul 22, 2026, there are 29.48M KRYS shares outstanding. The market capitalization of KRYS is $9.93B. In the past 24 hours, 289,000 KRYS shares were traded.
How to Buy Krystal Biotech Stock
Not sure how to invest in Krystal Biotech stock? Here's how.
Choose where to buy Krystal Biotech stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you decide where to buy Krystal Biotech stock.
Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Deposit funds into your investment account: Pick your payment method and add your info.
Analyze Krystal Biotech stock: The Krystal Biotech ticker symbol is KRYS. Is Krystal Biotech stock a good investment? Should you buy shares of KRYS? How do KRYS's underlying business fundamentals look? Do top analysts think Krystal Biotech is a good buy? Why has KRYS's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if KRYS is a good stock to buy).
Execute your KRYS buy order: Decide if you will purchase KRYS shares at the current market price or use a limit order to purchase KRYS stock at a specific price.
Get updates on your KRYS investment: Create a watchlist to keep tabs on your new investment in Krystal Biotech shares.
Step 1: Choose where to buy Krystal Biotech stock
You need an online brokerage account in order to access the NASDAQ market and buy KRYS stock.
A brokerage account allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. eToro gives you:
Invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to world markets: From Tech to Utilities, New York to Tokyo (for US users, only US stocks are available) ā you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (āthe BDā), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (āthe MSBā) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create your brokerage account
Now that you've selected the best brokerage, you need to fill out some personal info so you are able to buy KRYS today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Krystal Biotech stock
Once you have selected the best place to buy Krystal Biotech stock, it's important to evaluate their stock before you buy, so you truly understand the risk and upside.
Krystal Biotech stock data
KRYS Price
$336.80
1w %
-3.84%
1y %
121.72%
5y %
440.87%
P/E
43.46x
P/B
7.78x
P/S
23.64x
PEG
2.09x
Revenue
$417.30M
Earnings
$225.03M
Fore. Rev. Growth
27.16%
Fore. Earn. Growth
20.8%
Market Cap
$9.93B
Next Earnings
Aug 3, 2026
Next Dividend
N/A
KRYS Due Diligence Checks
WallStreetZen was created to help part-time investors do better fundamental analysis in minutes instead of hours.
There are more short-term assets than long-term liabilities on the KRYS balance sheet.
KRYS earnings of $207.32M is not sufficient to cover its interest payments.
KRYS's operating cash flow of $250.28M allows it to safely service it's debt of $9.11M.
There are more short-term assets than short-term liabilities on the KRYS balance sheet.
KRYS profit margin has gone up from 37.2% to 53.9% in the past year.
Failed Health Checks:
Total KRYS debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy KRYS stock, according to Wall Street analysts?
Out of 9 Equities analysts who research KRYS, the consensus analyst rating on KRYS is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest KRYS Analyst Forecasts
Debjit Chattopadhyay, a top 13% analyst from Guggenheim maintains KRYS with a strong buy rating and raises their KRYS price target from $224.00 to $284.00, on Feb 25, 2026.
Guggenheim's Debjit Chattopadhyay raised their price target on Krystal Biotech (NASDAQ: KRYS) by 26.8% from $224 to $284 on 2026/02/25. The analyst maintained their Strong Buy rating on the stock.
Krystal Biotech reported its Q4 and FY 2025 earnings.
Chattopadhyay said the results catalyzed their price target hike.
Geulah Livshits, a top 3% analyst from Chardan Capital maintains KRYS with a strong buy rating and raises their KRYS price target from $220.00 to $323.00, on Feb 18, 2026.
Roger Song, a top 16% analyst from Jefferies maintains KRYS with a strong buy rating and raises their KRYS price target from $310.00 to $371.00, on Feb 17, 2026.
Andrea Tan, a bottom 3% analyst from Goldman Sachs maintains KRYS with a strong buy rating and raises their KRYS price target from $206.00 to $327.00, on Feb 2, 2026.
Last year, KRYS earnings were $225.03M. During the past two year, KRYS's earnings have gone up by 97.84% per year. This was faster than the Biotechnology industry average of 11.9%.
Last year, KRYS revenue was $417.30M. Over the past two year, KRYS's revenue has increased by 108.55% per year. This was faster than the Biotechnology industry average of 31.71%.
No, Krystal Biotech doesn't provide an income stream by paying out dividends.
KRYS Social Trading Data
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your KRYS buy order
There are two primary types of orders:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are mostly sufficient.
Limit order: A limit order allows you to buy or sell a security at a specific price (or better). If you want to ensure you're buying or selling at a given price limit, use a limit order.
Hit the Open button and your broker will execute the order.
If you need additional help investing in stocks on eToro, watch the helpful video below:
How much does it cost to buy one Krystal Biotech share?
As of Jul 22, 2026, it costs $336.80 to buy one share of Krystal Biotech stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.297 shares of KRYS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.